Abstract

Oral Abstract: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status
Alessandra Cesano ... Elisabeth Paietta
Blood | VOL. 118
Alessandra Cesano, et. al.Alessandra Cesano ... Elisabeth Paietta
18 Nov 2011
FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia
Le Xuan Truong Nguyen ... Guido Marcucci
Blood | VOL. 134
Le Xuan Truong Nguyen, et. al.Le Xuan Truong Nguyen ... Guido Marcucci
13 Nov 2019
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Jorge Cortes ...
The Lancet Oncology | VOL. 19
Jorge Cortes, et. al.Jorge Cortes ...
31 May 2018
Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
Alexander E Perl ... Mark J Levis
Journal of Clinical Oncology | VOL. 31
Alexander E Perl, et. al.Alexander E Perl ... Mark J Levis
20 May 2013
View more papers

More From: Clinical Lymphoma Myeloma and Leukemia

Paper Title
Journal
Date
Author
CT-200 A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of Maat033 an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial
Florent Malard ... Mohamad Mohty
Clinical Lymphoma Myeloma and Leukemia | VOL. 24
Florent Malard, et. al.Florent Malard ... Mohamad Mohty
01 Sep 2024
Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario
Mayank Soni ... Dinesh Bhurani
Clinical Lymphoma Myeloma and Leukemia | VOL. 24
Mayank Soni, et. al.Mayank Soni ... Dinesh Bhurani
01 Sep 2024
Synchronous Diagnosis of Acute Promyelocytic Leukemia (APL) and Relapsed Breast Cancer (RBC)
Asmae Rasmaoui ... Abdellah Madani
Clinical Lymphoma Myeloma and Leukemia | VOL. 24
Asmae Rasmaoui, et. al.Asmae Rasmaoui ... Abdellah Madani
01 Sep 2024
AML-348 Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia
Jesse Tettero ... Jacqueline Cloos
Clinical Lymphoma Myeloma and Leukemia | VOL. 24
Jesse Tettero, et. al.Jesse Tettero ... Jacqueline Cloos
01 Sep 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.